Ellume Limited products

The Ellume COVID-19 Home Test is an over-the-counter, rapid self-test which detects SARS-CoV-2 antigen. The test is suitable for ages 2 years and above for over-the-counter home use in the U.S*. Clinically proven for use for people with and without symptoms, with accurate test results in 15 minutes. The app will guide you through the test including an integrated information video and step-by-step instructions. The sample is analyzed and the result is displayed on your phone after 15 minutes. Results are saved within the app and can be shared via email. The Ellume COVID-19 Home Test complies with CDC reporting requirements and automatically reports the required data to health authorities through our secure encrypted, HIPAA compliant, cloud connection.

In partnership with global diagnostics company QIAGEN®, Ellume has developed two rapid COVID-19 tests: the QIAreach™ SARS-CoV-2 Antigen Test**** for active infections and the QIAreach™ Anti-SARS-CoV-2 Total Test** for past infections. Both tests are now available in the U.S. The tests are run on the eHub platform, an easy-to-use and portable digital device that provides results in less than 15 minutes.

ellume·lab is a versatile, handheld digital device designed for healthcare professionals at the point of care. ellume·lab offers a growing range of highly accurate, rapid diagnostic tests for the detection of common infectious diseases. Two tests can be performed at the same time, with simple, animated on-screen instructions and rapid results in 15 minutes. The COVID Antigen test (for the detection of active COVID-19 infections) is currently available***. The COVID Serology test (for the detection of total antibodies to SARS-CoV-2) is pending regulatory clearance.

We have created a highly accurate digital test, which enables a user to detect influenza in 12 minutes. The Ellume Pandemic Influenza Self-test connects to a user’s smartphone and provides simple, step-by-step, on-screen instructions through the test’s app. The app also allows direct access to clinical advice and treatment. We are working closely with relevant health authorities to connect into aggregated data in real-time, allowing for immediate response during pandemic outbreaks.

We have developed a single use flu test that can detect influenza from the comfort of the user’s own home. The test connects to the user’s smartphone through the test’s designated app. Test results are displayed on the user’s phone within 12 minutes of completing the test.

We are bringing the next generation of Latent Tuberculosis Infection diagnostics to those who need it most. In partnership with QIAGEN®, we are advancing the way tuberculosis is diagnosed. Combining our technology with Qiagen’s market leading test, QuantiFERON®, we are taking testing out of the laboratory and into the community.

Our patented detection method uses unique fluorescent nanoparticles and a sophisticated reader system to achieve accurate results from a clinical sample within minutes. We create efficiencies using our platform technology across a range of diagnostic tests for consumers, healthcare professionals at the point-of-care and higher-throughput laboratories. Our strategy of using digital technology at the core of our products has enabled us to create better ways to diagnose illness, control disease and link to optimal therapy.